Mesa Laboratories/$MLAB
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Mesa Laboratories
Mesa Laboratories Inc manufactures life sciences tools and critical quality control products. It operates in four divisions: Sterilization and Disinfection Control, which manufactures and sells biological, chemical, and cleaning indicators used to assess the effectiveness of sterilization, decontamination, disinfection, and cleaning processes. Clinical Genomics division develops, manufactures, and sells highly sensitive, low-cost, high-throughput genetic analysis tools and related consumables. The Biopharmaceutical Development division develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. The Calibration Solutions division develops, manufactures, sells, and services quality control products.
Ticker
$MLAB
Sector
Primary listing
Industry
Life Sciences Tools & Services
Headquarters
Employees
730
ISIN
US59064R1095
Website
MLAB Metrics
BasicAdvanced
$507M
-
-$0.36
0.97
$0.64
0.69%
Price and volume
Market cap
$507M
Beta
0.97
52-week high
$155.12
52-week low
$83.68
Average daily volume
91K
Dividend rate
$0.64
Financial strength
Current ratio
0.626
Quick ratio
0.433
Long term debt to equity
55.861
Total debt to equity
121.286
Interest coverage (TTM)
1.48%
Profitability
EBITDA (TTM)
42.095
Gross margin (TTM)
63.12%
Net profit margin (TTM)
-0.82%
Operating margin (TTM)
7.29%
Effective tax rate (TTM)
133.12%
Revenue per employee (TTM)
$330,000
Management effectiveness
Return on assets (TTM)
2.50%
Return on equity (TTM)
-1.29%
Valuation
Price to revenue (TTM)
2.092
Price to book
3.17
Price to tangible book (TTM)
-4.27
Price to free cash flow (TTM)
11.915
Free cash flow yield (TTM)
8.39%
Free cash flow per share (TTM)
780.46%
Dividend yield (TTM)
0.69%
Forward dividend yield
0.69%
Growth
Revenue change (TTM)
11.47%
Earnings per share change (TTM)
-99.23%
3-year revenue growth (CAGR)
9.34%
10-year revenue growth (CAGR)
12.95%
3-year earnings per share growth (CAGR)
1.33%
10-year earnings per share growth (CAGR)
-17.94%
10-year dividend per share growth (CAGR)
0.32%
What the Analysts think about MLAB
Analyst ratings (Buy, Hold, Sell) for Mesa Laboratories stock.
Bulls say / Bears say
Mesa Laboratories reported a 17.5% increase in revenue for Q3 2025, reaching $62.84 million, indicating strong growth across key divisions. (nasdaq.com)
The Biopharmaceutical Development division showed the strongest core organic growth at 31.3% in Q3 2025, highlighting its potential as a significant revenue driver. (stocktitan.net)
Mesa Labs repaid $9.4 million in debt during Q3 2025, reducing their Total Net Leverage Ratio to 3.20x, demonstrating a commitment to strengthening their financial position. (nasdaq.com)
Despite strong operational performance, Mesa Labs reported a net loss in Q3 2025, primarily due to unrealized foreign currency losses and interest expenses, which could impact investor confidence. (stocktitan.net)
The Clinical Genomics division faced headwinds in China and North America, potentially affecting overall revenue growth and market expansion. (stocktitan.net)
Mesa Laboratories has a net cash position of -$179.32 million, indicating a significant level of debt that may pose financial risks. (stockanalysis.com)
Data summarised monthly by Lightyear AI. Last updated on 8 Jun 2025.
MLAB Financial Performance
Revenues and expenses
MLAB Earnings Performance
Company profitability
MLAB News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Mesa Laboratories stock?
Mesa Laboratories (MLAB) has a market cap of $507M as of June 20, 2025.
What is the P/E ratio for Mesa Laboratories stock?
The price to earnings (P/E) ratio for Mesa Laboratories (MLAB) stock is 0 as of June 20, 2025.
Does Mesa Laboratories stock pay dividends?
Yes, the Mesa Laboratories (MLAB) stock pays dividends to shareholders. As of June 20, 2025, the dividend rate is $0.64 and the yield is 0.69%. Mesa Laboratories has a payout ratio of 0% on a trailing twelve-month basis.
When is the next Mesa Laboratories dividend payment date?
The next Mesa Laboratories (MLAB) dividend payment date is unconfirmed.
What is the beta indicator for Mesa Laboratories?
Mesa Laboratories (MLAB) has a beta rating of 0.97. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.